IRIS
LAGHEZZA, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.439
AS - Asia 4.660
EU - Europa 4.223
SA - Sud America 1.323
Continente sconosciuto - Info sul continente non disponibili 679
AF - Africa 217
OC - Oceania 14
Totale 23.555
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.052
SG - Singapore 1.772
IT - Italia 1.557
CN - Cina 1.129
BR - Brasile 1.040
HK - Hong Kong 592
SE - Svezia 441
RU - Federazione Russa 435
FR - Francia 346
VN - Vietnam 335
DE - Germania 333
UA - Ucraina 266
FI - Finlandia 265
GB - Regno Unito 264
IN - India 195
CA - Canada 187
BD - Bangladesh 126
AR - Argentina 91
ID - Indonesia 70
IQ - Iraq 59
MX - Messico 53
EC - Ecuador 49
BE - Belgio 47
TR - Turchia 47
CI - Costa d'Avorio 45
ZA - Sudafrica 44
AT - Austria 43
CO - Colombia 42
PL - Polonia 42
JP - Giappone 40
VE - Venezuela 35
IE - Irlanda 33
PH - Filippine 30
PK - Pakistan 28
NL - Olanda 27
SA - Arabia Saudita 26
ES - Italia 25
LT - Lituania 22
EG - Egitto 20
SV - El Salvador 20
CH - Svizzera 19
CL - Cile 19
CR - Costa Rica 19
MY - Malesia 19
JO - Giordania 18
MA - Marocco 18
UZ - Uzbekistan 18
IL - Israele 17
KE - Kenya 17
KR - Corea 17
TT - Trinidad e Tobago 17
NI - Nicaragua 16
PY - Paraguay 16
TN - Tunisia 16
TW - Taiwan 16
GT - Guatemala 14
JM - Giamaica 14
PR - Porto Rico 14
IR - Iran 13
AU - Australia 12
CW - ???statistics.table.value.countryCode.CW??? 12
GP - Guadalupe 11
PE - Perù 11
PT - Portogallo 11
SC - Seychelles 11
OM - Oman 10
AE - Emirati Arabi Uniti 9
BO - Bolivia 9
HN - Honduras 9
LB - Libano 9
AL - Albania 8
BH - Bahrain 8
NP - Nepal 8
UY - Uruguay 8
CZ - Repubblica Ceca 7
DZ - Algeria 7
SN - Senegal 7
TH - Thailandia 7
AZ - Azerbaigian 6
BB - Barbados 5
DK - Danimarca 5
ET - Etiopia 5
RS - Serbia 5
AO - Angola 4
EE - Estonia 4
GE - Georgia 4
KG - Kirghizistan 4
KW - Kuwait 4
PA - Panama 4
SY - Repubblica araba siriana 4
ZW - Zimbabwe 4
BG - Bulgaria 3
GA - Gabon 3
HU - Ungheria 3
KH - Cambogia 3
KZ - Kazakistan 3
LY - Libia 3
PS - Palestinian Territory 3
A1 - Anonimo 2
AM - Armenia 2
Totale 22.847
Salva come PNG Salva come JPEG
Città #
Ashburn 1.409
Fairfield 916
San Jose 897
Singapore 877
Chandler 807
Woodbridge 693
Jacksonville 599
Hong Kong 571
Milan 534
Houston 476
Cambridge 424
Seattle 373
Council Bluffs 356
Nyköping 347
Beijing 310
Ann Arbor 307
Wilmington 304
Dallas 194
New York 187
Lawrence 181
Roxbury 176
Lauterbourg 173
Rome 163
Los Angeles 151
Bari 150
Nanjing 146
Santa Clara 145
Princeton 133
Ho Chi Minh City 128
Boardman 121
Helsinki 111
Des Moines 103
Washington 96
São Paulo 91
Inglewood 89
Munich 72
Brooklyn 65
Hanoi 65
Chicago 59
Naples 57
London 49
San Diego 48
Figino 47
Brussels 46
Frankfurt am Main 46
Jakarta 46
North Bergen 46
Abidjan 45
Buffalo 45
Turin 44
Jiaxing 39
Moscow 39
Nanchang 39
Phoenix 39
Hebei 38
Tokyo 38
Atlanta 35
Columbus 35
Montreal 34
Rio de Janeiro 34
Shenyang 33
Toronto 33
Warsaw 32
Changsha 31
Dublin 31
Orem 31
Chennai 30
Denver 29
Marseille 29
San Francisco 28
Florence 27
Baghdad 26
Johannesburg 26
Dong Ket 25
Guangzhou 24
Poplar 23
Belo Horizonte 22
Manchester 22
Paris 22
Tianjin 22
Fragagnano 21
Bologna 20
Brasília 19
Falkenstein 19
San Salvador 19
Boston 18
Curitiba 18
Guayaquil 18
Mexico City 18
Nuremberg 18
Tashkent 18
Boydton 17
Campinas 16
Managua 16
Amman 15
Dearborn 15
Pune 15
Shanghai 15
Amsterdam 14
Augusta 14
Totale 14.777
Salva come PNG Salva come JPEG
Nome #
Comparison Between Different Flavored Olive Oil Production Techniques: Healthy Value and Process Efficiency 247
Catechol-based matrix metalloproteinase inhibitors with additional antioxidative activity 246
An efficient synthesis of the optically active isomers of 2H-1,4-benzoxazine derivatives, novel KATP channel modulators 220
Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin 220
New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity 219
Natural Scaffolds with Multi-Target Activity for the Potential Treatment of Alzheimer’s Disease 213
On the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles 209
DEVELOPMENT OF PHENOXYALKYLPIPERIDINES AS HIGH-AFFINITY SIGMA-1 (s1) RECEPTOR LIGANDS WITH POTENT ANTI-AMNESIC ACTIVITY 205
Convenient synthesis of some 3-phenyl-1-benzofuran-2-carboxylic acid derivatives as new potential inhibitors of CLC-Kb channels 201
Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis 189
A Review of Recent Patents (2016-2019) on Plant Food Supplements with Potential Application in the Treatment of Neurodegenerative and Metabolic Disorders 186
Derivatives of Tenuazonic Acid as Potential New Multi-Target Anti-Alzheimer’s Disease Agents 186
Beyond the Canonical Endocannabinoid System. A Screening of PPAR Ligands as FAAH Inhibitors 182
Antioxidant Activity of Uva di Troia Canosina: Comparison of Two Extraction Methods 179
Kidney CLC-K Chloride Channels Show Differential Pharmacological Profiles Depending on the Heterologous Expression System 178
1,3,5-triazine derivatives as dual inhibitors of 5-HT6R/FAAH in search of new therapy for Alzheimer's disease 175
An update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligands 175
ChemInform Abstract: Convenient Synthesis of Some 3-Phenyl-1-benzofuran-2-carboxylic Acid Derivatives as New Potential Inhibitors of CLC-Kb Channels. 173
Betulinic acid is a PPARγ antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis 171
Antiproliferative activity evaluation of a series of N-1,3-benzothiazol-2-ylbenzamides as novel apoptosis inducers 171
Bone-seeking matrix metalloproteinase inhibitors for the treatment of skeletal malignancy 168
Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARα and PPARγ agonist activity 166
Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors 166
Abstract P6-16-02: Treatment of skeletal metastatic breast cancer with bone seeking matrix metalloproteinase inhibitors 164
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome. 164
An Effective Virtual Screening Protocol to Identify Promising p53-MDM2 Inhibitors 163
Abstract 4858: A novel strategy for the selective and tissue specific inhibition of MMPs in active breast cancer to bone metastases 159
Bone seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth 159
Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode 159
ANTIDIABETIC AND ANTIOBESITY ACTIVITY OF A NOVEL DUAL PEROXYSOME PROLIFERATOR ACTIVATED RECEPTORS ALPHA/GAMMA LIGAND: A NEW SCAFFOLD MOLECULE DEVOID OF SOME SIDE-EFFECTS OF PPAR LIGANDS? 158
Comparative LC Enantioseparation of Novel PPAR Agonists on Cellulose- and Amylose-Based Chiral Stationary Phases 158
Abstract 398: Specific skeletal targeting of MMP-2 inhibitors for the treatment of bone metastatic breast cancer 156
Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors 154
New Approaches to Cancer Therapy: Combining Fatty Acid Amide Hydrolase (FAAH) Inhibition with Peroxisome Proliferator-Activated Receptors (PPARs) Activation 152
Abstract P6-12-10: Bone seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth 150
Structural requisites of 2-(p-chlorophenoxy)propionic acid analogues for activity on native rat skeletal muscle chloride conductance and on heterologously expressed CLC-1 149
A New Series of Aryloxyacetic Acids Endowed with Multi-Target Activity towards Peroxisome Proliferator-Activated Receptors (PPARs), Fatty Acid Amide Hydrolase (FAAH), and Acetylcholinesterase (AChE) 149
Combining fatty acid amide hydrolase (FAAH) inhibition with peroxisome proliferator-activated receptor (PPAR) activation: a new potential multi-target therapeutic strategy for the treatment of Alzheimer’s disease 147
Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption 146
A Chemical Modification of a Peroxisome Proliferator-Activated Receptor Pan Agonist Produced a Shift to a New Dual Alpha/Gamma Partial Agonist Endowed with Mitochondrial Pyruvate Carrier Inhibition and Antidiabetic Properties 145
AGONISTI DEI RECETTORI NUCLEARI PPARs COME POTENZIALI NUOVI AGENTI TERAPEUTICI PER IL TRATTAMENTO DELLA SINDROME METABOLICA. 144
Open tubular columns containing the immobilized ligand binding domain of peroxisome proliferator-activated receptors α and γ for dual agonists characterization by frontal affinity chromatography with mass spectrometry detection 143
Insights into the complex formed by Matrix Metalloproteinase-2 and alloxan inhibitors: molecular dynamics simulations and free energy calculations 143
Analoghi degli acidi clofibrici e loro uso come ligandi dei recettori nucleari peroxisome proliferator activated receptor (PPAR) alfa e gamma 142
A new benzoxazine compound blocks KATP channels in pancreatic beta cells: molecular basis for tissue selectivity in vitro and hypoglycaemic action in vivo 141
A Series of Ferulic Acid Amides Reveals Unexpected Peroxiredoxin 1 Inhibitory Activity with in vivo Antidiabetic and Hypolipidemic Effects 141
Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase 140
Crystal structure of the peroxisome proliferator-activated receptor γ (PPARγ) ligand binding domain complexed with a novel partial agonist: A new region of the hydrophobic pocket could be exploited for drug design 139
Importance of Biometals as Targets in Medicinal Chemistry: An Overview about the Role of Zinc (II) Chelating Agents 139
Screening of saponins and sapogenins from Medicago species as potential PPARγ agonists and X-ray structure of the complex PPARγ/caulophyllogenin 139
New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression 138
Structural development studies of PPARs ligands based on tyrosine scaffold. 136
Molecular determinants for the activating/blocking actions of the 2H-1,4-benzoxazine derivatives, a class of potassium channel modulators targeting the skeletal muscle KATP channels 136
Single-nucleotide polymorphism of PPARγ, a protein at the crossroads of physiological and pathological processes 136
Agonisti dei Recettori Nucleari PPARs come Potenziali Nuovi Agenti Terapeutici per il Trattamento della Sindrome Metabolica 134
Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor alpha/gamma ligand LT175 134
Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation 133
(contributo in convegno) MOLECULAR DETERMINANTS FOR NUCLEAR RECEPTORS SELECTIVITY; CHEMOMETRIC ANALYSIS, DOCKINGS AND SITE-DIRECTED MUTAGENESIS OF DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS α/γ AGONISTS 131
(2-Aminobenzothiazole)-Methyl-1,1-bisphosphonic acids: Targeting matrix metalloproteinase 13 inhibition to the bone 131
A Chemoinformatics Search for Peroxisome Proliferator-Activated Receptors Ligands Revealed a New Pan-Agonist Able to Reduce Lipid Accumulation and Improve Insulin Sensitivity 131
Seeking for non-zinc-binding MMP-2 inhibitors: Synthesis, biological evaluation and molecular modelling studies 130
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. 130
Frontal affinity chromatography with MS detection of the ligand binding domain of PPARγ receptor: ligand affinity screening and stereoselective ligand–macromolecule interaction. 129
Natural Compounds for the Prevention and Treatment of Cardiovascular and Neurodegenerative Diseases 129
Synthesis, Biological Evaluation, and Molecular Modeling Investigation of Chiral Phenoxyacetic Acid Analogues with PPARalpha and PPARgamma Agonist Activity 128
Synthesis of novel benzothiazole amides: Evaluation of PPAR activity and anti-proliferative effects in paraganglioma, pancreatic and colorectal cancer cell lines 128
In-vivo administration of CLC-K kidney chloride channels inhibitors increases water diuresis in rats: A new drug target for hypertension? 128
Structural basis of the transactivation deficiency of human PPARγ F360L mutant associated with familial partial lipodystrophy 127
Mimic catechins to develop selective MMP-2 inhibitors 126
Development of novel phenoxyalkylpiperidines as high-affinity Sigma-1 (σ1) receptor ligands with potent anti-amnesic effect 124
Antioxidant activity of Uva di Troia ad acino piccolo: comparison of different extraction methods 123
Rivastigmine structure-based hybrids as potential multi-target anti-Alzheimer’s drug candidates 122
A New Antidiabetic Agent Showing Short- and Long-Term Effects Due to Peroxisome Proliferator-Activated Receptor Alpha/Gamma Dual Agonism and Mitochondrial Pyruvate Carrier Inhibition 120
Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption 120
CLC-K kidney chloride channels as drug target for hypertension: effects of acute in vivo administration to rats of newly synthesized inhibitors 120
Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARgamma Agonists and their Antidiabetic Effects on Type 2 Diabetes 120
AMALPHI: A Machine Learning Platform for Predicting Drug-Induced PhospholIpidosis 118
Dualistic actions of cromakalim and new potent 2H-1,4-benzoxazine derivatives on the native skeletal muscle K(ATP) channel 118
A NEW ANTIDIABETIC AGENT SHOWING PPARα/γ DUAL AGONISM AND MITOCHONDRIAL PYRUVATE CARRIER INHIBITION 117
Selective MMP inhibitors for the treatment of skeletal malignancy. 113
Cisplatin and zoledronic acid: two drugs combined in a Pt(II) complex with potential antitumor activity towards bone tumors and metastases 112
Identification of novel matrix metalloproteinase inhibitors by screening of phenol fragments library 112
Changing the binding mode to peroxisome proliferator activated receptor (PPAR) alpha/gamma: a new ligand with improved antidiabetic and antiobesity properties 112
Improved lipid metabolism and reduced fat deposition in a mouse model of diet-induced obesity (DIO) with a new dual PPARα/γ ligand 111
BIOLOGICAL ACTIVITY OF NEW POTENT 2H-1,4-BENZOXAZINE DERIVATIVES ON THE NATIVE SKELETAL MUSCLE KATP CHANNEL 111
Resveratrol and Its Metabolites Bind to PPARs 111
Natural scaffolds with potential metal chelating activity for the multi-target therapy of Alzheimer's Disease: a preliminary study 111
Novel Phenothiazine/Donepezil-Like Hybrids Endowed with Antioxidant Activity for a Multi-Target Approach to the Therapy of Alzheimer’s Disease 110
KIDNEY CLC-K CHLORIDE CHANNELS SHOW DIFFERENTIAL PHARMACOLOGICAL PROFILES DEPENDING ON THE HETEROLOGOUS EXPRESSION SYSTEM 109
Structural nucleotide analogs are potent activators/inhibitors of pancreatic beta-cell KATP channels: an emerging mechanism supporting their use as anti-diabetic drugs. 108
Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13 105
Natural compounds as FAAH inhibitors: preliminary screening and potential developments 105
Structure-based design of novel donepezil-like hybrids for a multi-target approach to the therapy of Alzheimer's disease 105
Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies. 104
Sintesi e valutazione biologica di nuovi solfonil fosfonati come inibitori di metalloproteinasi di matrice 102
Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors alpha/gamma agonists 101
Probing the S1’ Site for the Identification of Non-Zinc- Binding MMP-2 Inhibitors 100
Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors alpha/gamma dual agonists 98
Peroxisome Proliferator Activated Receptor (PPAR) agonists as Fatty Acid Amide Hydrolase (FAAH) inhibitors: screening and preliminary structure-activity relationships 98
CC48 a new CB2R agonist/FAAH inhibitor dual drug blocks gastric cancer progression and overcomes paclitaxel resistance 97
Totale 14.420
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.495
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.495
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022982 0 0 0 0 44 63 54 55 72 67 229 398
2022/20232.130 358 175 128 180 276 288 21 232 357 19 54 42
2023/2024900 63 127 53 59 94 229 51 48 22 33 34 87
2024/20253.261 153 71 288 151 86 203 316 311 154 192 396 940
2025/20267.600 913 429 509 957 733 395 780 258 675 775 276 900
2026/20272.534 243 413 846 1.023 9 0 0 0 0 0 0 0
Totale 23.555